Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical research update: zoledronate

J J Body1

  • 1Laboratory of Endocrinology/Breast Cancer Research, Institut J. Bordet, University Libre de Bruxelles, Brussels, Belgium.

Cancer
|November 15, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone strain index improves 10-year fracture risk prediction beyond bone mineral density and FRAX® in community-dwelling older women: A study of the FRISBEE cohort.

Bone·2026
Same author

Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Selection for treatment of patients at high risk of fracture by the short versus long term prediction models - data from the Belgian FRISBEE cohort.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

The effect of fracture recency on observed 5-year fracture probability: A study based on the FRISBEE cohort.

Bone reports·2023
Same author

Are there specific clinical risk factors for the occurrence of multiple fractures? The FRISBEE study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

Distribution of Fracture Sites in Postmenopausal Overweight and Obese Women: The FRISBEE Study.

Calcified tissue international·2022
Same journal

Toward exercise as standard care for older cancer survivors.

Cancer·2026
Same journal

Maintenance therapy in gynecologic malignancies: Current and future state.

Cancer·2026
Same journal

Long-term outcomes of evolving treatment regimens in Ewing sarcoma survivors diagnosed 1970-1999: A report from the Childhood Cancer Survivor Study.

Cancer·2026
Same journal

Large-scale osteosarcoma sequencing reveals age-associated genomic architectures.

Cancer·2026
Same journal

EZH2 inhibitor tazemetostat voluntarily withdrawn from market.

Cancer·2026
Same journal

Nivolumab and chemotherapy combination approved for previously untreated Hodgkin lymphoma.

Cancer·2026
See all related articles

Zoledronate, a potent bisphosphonate, effectively treats hypercalcemia and inhibits bone resorption in cancer patients. Early trials show faster onset and longer duration than existing therapies, with good tolerability.

Area of Science:

  • Oncology
  • Pharmacology
  • Bone Metabolism

Background:

  • Bisphosphonates reduce skeletal events in metastatic breast carcinoma and multiple myeloma.
  • More potent bisphosphonates are needed to simplify therapy and improve effectiveness.

Purpose of the Study:

  • To evaluate the efficacy and safety of zoledronate, a novel potent bisphosphonate, in patients with cancer.
  • To assess zoledronate's potential in treating hypercalcemia and lytic bone metastases.

Main Methods:

  • Phase I multicenter trial in patients with tumor-induced hypercalcemia.
  • Single intravenous infusions of zoledronate at doses of 0.02 and 0.04 mg/kg.
  • Phase I trial in patients with lytic bone metastases, receiving monthly short infusions (0.1-8.0 mg).

Related Experiment Videos

Main Results:

  • Single zoledronate doses normalized calcium levels in 93% of hypercalcemic patients within 2 days.
  • Median duration of action was 33 days, indicating faster onset and longer effect than other bisphosphonates.
  • Zoledronate showed analgesic effects and greater inhibition of bone resorption markers compared to pamidronate in patients with bone metastases.

Conclusions:

  • Zoledronate is a highly potent bisphosphonate with a favorable profile for treating cancer-related bone complications.
  • Convenient short intravenous infusions of zoledronate demonstrate marked and prolonged inhibition of bone resorption.
  • Further trials are warranted to confirm zoledronate's impact on bone metastasis morbidity with prolonged treatment.